BLA 761094 · Dompe Farmaceutici
Oxervate
Cenegermin-Bkbj · Ophthalmic · Recombinant Human Nerve Growth Factor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 20, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Aug 22, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
20
4 Phase 3, 2 recruiting
FAERS reports
13,495
1,498 serious, 220 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 11, 2026.
OXERVATE ® (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis. OXERVATE is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis. ( 1 )
Mechanism: Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (i.e., TrkA) and low-affinity (i.e. p75NTR) nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 22, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- OXERVATE · CENEGERMIN-BKBJ 0.002%(20MCG/ML) · SOLUTION, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cenegermin" as an intervention, any sponsor and status, largest first.
- A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.Pivotal-lookingCompleted
Dompé Farmaceutici S.p.AIndustry
NCT06244316 · 317 participants · Start Jan 22, 2024 · Primary completion Dec 4, 2024
Drug: rhNGF 5 μg/mL; rhNGF 10 μg/mL and 1 more · For: Dry Eye Disease
Sites: Chandler, Arizona; Torrance, California; Colorado Springs, Colorado · 14 sites in all
- Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)Pivotal-lookingRecruiting
Dompé Farmaceutici S.p.AIndustry
NCT07453888 · 272 participants (planned) · Start Jul 1, 2026 · Primary completion Sep 2027
Drug: Cenegermin · For: Non-Arteritic Anterior Ischemic Optic Neuropathy
Sites: Los Angeles, California; Newport Beach, California; Palo Alto, California · 38 sites in all
- A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry EyePivotal-lookingCompleted
Dompé Farmaceutici S.p.AIndustry
NCT03982368 · 261 participants · Start Jun 10, 2019 · Primary completion Jul 15, 2020
Drug: rhNGF 20 μg/ml; rhNGF 20 μg/ml + vehicle · For: Dry Eye Syndrome
Sites: Glendale, California; Newport Beach, California; Rancho Cordova, California · 12 sites in all
- Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.Pivotal-lookingCompleted
Dompé Farmaceutici S.p.AIndustry
NCT01756456 · 174 participants · Start Jan 2013 · Primary completion Apr 2015
Drug: rhNGF 10 μg/ml; rhNGF 20 μg/ml · For: Neurotrophic Keratitis; Keratitis; Corneal Ulcer
Sites: Dijon, France; Limoges, France; Paris, France · 34 sites in all
- An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCEDPivotal-lookingRecruiting
Dompé Farmaceutici S.p.AIndustry
NCT07519902 · 150 participants (planned) · Start Jun 2, 2026 · Primary completion Dec 2027
Drug: Cenegermin · For: Persistent Corneal Epithelial Defect
Sites: Huntington Beach, California; Laguna Hills, California; Loma Linda, California · 77 sites in all
- An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry EyePivotal-lookingCompleted
Dompé Farmaceutici S.p.AIndustry
NCT03019627 · 150 participants · Start Jan 20, 2017 · Primary completion Aug 31, 2017
Drug: NGF · For: Dry Eye
Sites: Philadelphia, Pennsylvania
- Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)Pivotal-lookingCompleted
Dompé Farmaceutici S.p.AIndustry
NCT05133180 · 104 participants · Start Jan 19, 2022 · Primary completion Sep 22, 2022
Drug: Oxervate · For: Dry Eye
Sites: Glendale, California; Newport Beach, California; Baltimore, Maryland · 10 sites in all
- Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye DiseasePivotal-lookingCompleted
Dompé Farmaceutici S.p.AIndustry
NCT05136170 · 85 participants · Start Jan 27, 2022 · Primary completion May 24, 2023
Drug: Cenegermin · For: Dry Eye Disease
Sites: Glendale, California; Baltimore, Maryland; Boston, Massachusetts · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye pain6,508
- eye irritation2,111
- product dose omission issue1,456
- ocular hyperaemia1,360
- photophobia1,209
- vision blurred1,053
- eye swelling959
- wrong technique in product usage process949
- ocular discomfort908
- lacrimation increased822
- eyelid pain797
- headache773
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2019 | 488 |
| 2020 | 661 |
| 2021 | 1,094 |
| 2022 | 1,926 |
| 2023 | 2,337 |
| 2024 | 2,274 |
| 2025 | 3,179 |
| 2026 | 1,535 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Oxervate (Cenegermin-Bkbj)
2024 spending
$715M
Beneficiaries
4,781
18,294 claims
Per beneficiary
$149,456
$2,011.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $215,418,307 |
| 2021 | $274,796,161 |
| 2022 | $367,261,094 |
| 2023 | $493,161,481 |
| 2024 | $714,549,320 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. · Ophthalmology 2020 · Multicenter Study, Randomized Controlled Trial
- Topical Cenegermin for Pediatric Neurotrophic Keratopathy: A Review of the Literature and Systematic Review.
Bakr M, Eleiwa TK, Saeed HN, et al. · Cornea 2025 · Systematic Review
- Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.
Wirta D, Lipsky W, Toyos M, et al. · BMC Ophthalmol 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
- Systematic Literature Review on the Effect of Cenegermin on Corneal Sensation and Innervation in Patients with Neurotrophic Keratopathy.
Fung SSM, Campos C, Weiss J, et al. · J Ocul Pharmacol Ther 2026 · Systematic Review
- The Efficacy and Safety of Recombinant Human Nerve Growth Factor (rhNGF) in Patients With Dry Eye Disease: A Systematic Review and Meta-analysis.
Qutub MF, Alajmi TS, Alnabihi AN, et al. · Int Ophthalmol 2026 · Systematic Review, Meta-Analysis
Sponsor: Dompe Farmaceutici
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.